Akebia Therapeutics (AKBA) 8.95 $AKBA Akebia Announces

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 5:17 AM

Akebia Therapeutics (AKBA) 8.95 $AKBA

Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
BusinessWire - Mon May 23, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today presented positive results from a drug-drug interaction study of vadadustat, the Company's oral therapy for the treatment of anemia related to chronic kidney disease (CKD). The study demonstrated that vadadustat has no clinically significant interaction with CYP2C9-sensitive substrates and, therefore, may be administered with medications metabolized by CYP2C9 without the need to modify the dose of the co-administered drug. CYP2C9 is involved in the metabolism of many commonly prescribed drugs, such as cholesterol and blood pressure medications. These results were presented at the 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Vienna, Austria.
AKBA: 8.95 (-0.06)

Akebia to Present at the 2016 UBS Global Healthcare Conference
BusinessWire - Mon May 16, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Monday, May 23, 2016, at 4:00 p.m. Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York City.
AKBA: 8.95 (-0.06)

Akebia Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 5:04PM CDT
CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $25.8 million in its first quarter.
AKBA: 8.95 (-0.06)

Akebia Announces First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 05, 3:05PM CDT
--- Announces Positive Data from Japanese Ethnobridging Study for Vadadustat -
AKBA: 8.95 (-0.06)

Commit To Purchase Akebia Therapeutics At $7.50, Earn 30.1% Annualized Using Options
StockOptionsChannel.com - Wed May 04, 10:48AM CDT
Investors eyeing a purchase of Akebia Therapeutics Inc shares, but tentative about paying the going market price of $9.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AKBA: 8.95 (-0.06)

Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings
BusinessWire - Tue Apr 26, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Phase 2 results for vadadustat in dialysis patients with anemia related to chronic kidney disease (CKD), including new pharmacokinetic data, will be presented in a poster presentation at the National Kidney Foundation 2016 Spring Clinical Meetings taking place in Boston from April 27-May 1.
AKBA: 8.95 (-0.06)

Akebia Therapeutics (AKBA): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:57AM CDT
Akebia Therapeutics (AKBA) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
AKBA: 8.95 (-0.06)

Akebia to Present at the 15th Annual Needham Healthcare Conference
BusinessWire - Tue Apr 05, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 10:00 a.m. Eastern Time. The conference is being held at The Westin Grand Central Hotel in New York City.
AKBA: 8.95 (-0.06)

Akebia Announces Fourth Quarter and Full-Year 2015 Financial Results
BusinessWire - Mon Mar 14, 3:05PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF), today announced financial results for the fourth quarter and full year ended December 31, 2015.
AKBA: 8.95 (-0.06)

Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat
BusinessWire - Wed Mar 09, 8:47AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that the Opposition Division (OD) of the European Patent Office (EPO) has revoked FibroGen, Inc.'s European Patent EP 1 463 823 (the '823 patent) in its entirety.
AKBA: 8.95 (-0.06), FGEN: 19.13 (+0.20)

Akebia to Host Conference Call on March 14th to Discuss Full-Year 2015 Financial Results and Corporate Highlights
BusinessWire - Tue Mar 08, 3:05PM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it will host a conference call on Monday, March 14, 2016 at 4:30 PM ET to discuss the financial results for the year ended December 31, 2015, and recent corporate highlights.
AKBA: 8.95 (-0.06)

Commit To Buy Akebia Therapeutics At $5, Earn 20.3% Annualized Using Options
StockOptionsChannel.com - Wed Feb 03, 10:43AM CST
Investors considering a purchase of Akebia Therapeutics Inc stock, but cautious about paying the going market price of $7.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AKBA: 8.95 (-0.06)

Akebia to Present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Mon Feb 01, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 11:30 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City.
AKBA: 8.95 (-0.06)

Smart Money Highlights Oversold Stocks in Small Cap Biotechs
ACCESSWIRE - Tue Jan 19, 10:22AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Biotech has taken a big hit so far in 2016. At the turn of the New Year, the iShares Nasdaq Biotechnology (NASDAQ:IBB) traded at $340. At the end of last week, the index closed out at $284 - a 16% decline across a two-week period. Some companies, of course, have suffered more than others. This is especially true in the development stage as investors pull capital out of riskier small caps. Not all companies warrant their declines, however, and market weakness looks to have left a few stocks oversold. At times like these, following the smart money can help us to identify the oversolds. Here are four companies with top investor backing that could be trading at a significant discount.
VRTX: 97.00 (+0.79), CRBP: 2.77 (-0.08), RPRX: 2.12 (+0.32), IBB: 289.44 (+1.76), AKBA: 8.95 (-0.06), EPZM: 10.36 (+0.10)

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 7:44AM CST
Akebia Therapeutics (AKBA) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AKBA: 8.95 (-0.06)

Biotech On the Edge? Try Better-Performing Health Care ETFs
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 12:02PM CST
The year 2016 started with another spell of biotech meltdown. Look at these health care ETFs that were relatively better performers in the stressed space.
IHF: 128.52 (-0.41), BBC: 19.90 (-0.10), SPY: 217.12 (+0.35), IBB: 289.44 (+1.76), EPZM: 10.36 (+0.10), AKBA: 8.95 (-0.06), IHI: 143.90 (+1.09), IXJ: 105.26 (+0.51), XLV: 75.20 (+0.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...